CYP2C19 and acute coronary syndrome: Since genetic testing is increasingly widespread, the Clinical Pharmacogenetics Implementation Consortium provided guidelines for clopidogrel therapy in acute coronary syndromes/PCI patients whose CYP2C19 genetic information is available [7].